

Navigating Through the Rapidly Evolving Treatment Landscape for GI Cancers: A Clinical & Patient-Centric Approach Towards Implementing Immunotherapy

**Saturday,
10 September 2022**

13:00 – 14:30 (CEST)

7.1.D – Dijon Auditorium, Hall 7, Level 7.1
Paris Expo Porte de Versailles
Paris, France

Chair



Michel Ducreux

Head, Gastrointestinal Oncology Unit and Gastrointestinal Oncology Tumor Board
Gustave Roussy
Professor of Oncology
University of Paris-Saclay
Paris, France

Faculty



Richard Finn

Professor of Medicine
Geffen School of Medicine
Department of Medicine, Division of Hematology/Oncology, UCLA
Los Angeles, California, USA



Yelena Janjigian

Chief, Associate Attending Gastrointestinal Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York City, New York, USA



Markus Moehler

Head, Gastrointestinal Oncology
Johannes-Gutenberg-University Clinic
Mainz, Germany



Arndt Vogel

Managing Senior Consultant and Professor
Department of Gastroenterology, Hepatology and Endocrinology
Hannover Medical School
Hannover, Germany

Agenda

13:00 – 13:05	Welcome and introductions <i>Michel Ducreux</i>
13:05 – 13:20	Moving the needle in HER2 positive gastroesophageal cancer <i>Yelena Janjigian</i>
13:20 – 13:35	Changing GEC patient care with IO plus chemotherapy as first-line treatment <i>Markus Moehler</i>
13:35 – 13:45	The IO revolution of patient treatment in HCC <i>Richard Finn</i>
13:45 – 14:00	Changing the treatment paradigm in first-line biliary tract cancers <i>Arndt Vogel</i>
14:00 – 14:10	Treating GI patients in Europe based on tumor characteristics <i>Michel Ducreux</i>
14:10 – 14:30	Q&A session <i>All panelists</i>

Agenda may be subject to change pending speaker confirmation